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The usage of natural sources like lichen extracts and their metabolites as anti-inflammatory agents is well known for 
ages. Based on the data of the folklore and documented books, researchers tested lichens and their products for anti-
inflammatory properties and they identified many therapeutic agents used to diagnosis acute and chronic inflammation with 
lesser side effects. In this study, we aimed to examine the acetone extract of Cladonia corniculata(AE)and its metabolites 
for in vitro anti-inflammatory and anti-gout effects. Through chemical investigation, we have successfully isolated and 
identified three known dibenzofurans, namely alectosarmentin 1, porphyrilic acid 2, and strepsilin 3 from the AE. All 
isolated dibenzofurans1-3 showed prominent inhibition of cyclooxygenase enzymes, whereas compounds 1 and 2 exhibited 
noticeable inhibition of 5-lipoxygenase enzyme. Only compound 2 showed significant inhibition of xanthine oxidase 
enzyme with an IC50 value of 80.17±0.66 µg/mL, while standard drug allopurinol with 9.10±0.64 µg/mL. The results 
indicate that C. corniculatacan be a favourable natural source for the treatment of inflammation and gout and these actions 
are linked to the natural active dibenzofurans1-3. 
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Lichens are recognized as an integral part of all 
ecosystems that can colonize and grow on bare rock 
surfaces, soil, trees, or even in intertidal zones and 
freshwater streams1. It has been reasoning that lichens 
produced unique substances that support their survival 
and growth in extreme conditions2. Different groups 
have applied chromatography techniques to analyse 
lichen extracts and elucidated approximately 1050 
unique phytoconstituents, to date, which falls in the 
classes of carbohydrates, amino-acid derivatives, 
chromones, xanthones, anthraquinones and 
naphthoquinones, depsides, tridepsides, depsidones, 
steroids, etc.3,4 Among all classes of lichen constituents, 
depsidones are the most remarkable secondary 
metabolites, comprising of two 2,4-dihydroxybenzoic 
acid rings connected by both ester and ether bonds. 
Also, they are well-acknowledged to have antibacterial, 




Cladonia genus belongs to family Cladoniaceae 
comprising about 400 species around the world, well 
recorded in the flora of Bhutan, India, Nepal, Himalayas, 
Thailand, and Vietnam6. Cladonia corniculata Ahti & 
Kashiwis a fruticose lichen, usually called as “Cup 
Lichen”.7 In the folklore, Cladonia species has wide 
applications in the treatment of microbial infections, 
inflammation, and tumours. Mainly, the Asian tribes 
used C. corniculata in the treatment of microbial 
infections and chronic inflammation. Biologically, 
Cladonia reported for anticancer8,9, antifungal10,11, 
antioxidant9, anti-microbial9, anti-inflammatory12, 
allelopathic13 and bioherbicidal13 potentialities. To date, 
no proper chemical investigation has attempted to 
evaluate the chemical constituents of whole lichen  
C. corniculata. Thus, based on the reports of the folklore 
and publications on Cladonia genus as good source for 
anti-inflammatory agents, the present study aims to 
examine the phyto-constituents present in the acetone 
extractof under-investigated lichen C. corniculata (AE) 
employing chromatography and to monitor  
anti-inflammatory and anti-gout effects of identified 
secondary metabolites. 
 
Results and Discussion 
 
Chemistry 
Three known dibenzofurans (1-3) were successfully 
identified from the AE by utilizing chromatographic 
and analyses of their spectral NMR data and elemental 




composition. The obtained data were interrelated with 
those reported in the previous literature.  
 
Compound 1 [Alectosarmentin]14(Figure 1): 
m.p.290-291°C. Rf: 0.6 (hexane:ethyl acetate, 1:1); 
1H NMR (400 MHz, DMSO-d6): δ2.27 (s, 1H, OH), 
2.98 (s, 1H, OH), 3.93 (s, 1H, OH), 5.03 (s, 1H, OH), 
6.35 (s, 1H, Ar-H), 6.45 (s, 1H, Ar-H), 7.12-7.13 (d, 
2H,J= 4 Hz, Ar-H), 7.61-7.63 (d, 2H,J= 8 Hz, Ar-H) 
(Fig. S1);13C NMR (400 MHz, DMSO-d6): δ94.96  
(C-8), 100.15 (C-6), 104.82 (C-4), 116.49 (C-12/14), 
122.48 (C-10), 131.48 (C-11/15), 136.89 (C-2), 
146.42 (C-1), 158.13 (C-9), 160.36 (C-13), 160.49 
(C-5), 164.68 (C-7), 175.78 (C-3) (Fig. S2). 
Anal.Calcd for: C,62.94; H,3.52. Found: C,62.96; 
H,3.54%. ESI-MS: Calcd m/z for C15H10O6: 286.23 
[M].Found: 285.14 [M + H+], 287.24 [M - H+]  
(Fig. S3). 
 
Compound 2 [Porphyrilic acid]15,16(Figure 1): 
m.p.301-302°C. Rf: 0.5 (hexane:ethyl acetate, 1:1); 
1H NMR (400 MHz, DMSO-d6): δ2.97 (s, 1H, OH), 
3.55 (s, 1H, OH), 3.85 (s, 3H, OCH3), 3.87 (s, 3H, 
OCH3), 5.03 (s, 1H, OH), 6.23 (d, 1H,J= 1 Hz, Ar-H), 
6.24-6.25 (d, 1H, J= 4 Hz, Ar-H), 6.85-6.87 (d, 1H,  
J= 8 Hz, Ar-H), 7.02-7.06 (m, 2H, Ar-H)  
(Fig. S4);13C NMR (400 MHz, DMSO-d6): δ57.07 (C-
10), 57.81 (C-17), 93.54 (C-8), 98.70 (C-6), 106.03  
(C-4),113.24 (C-15), 116.39 (C-12), 121.00 (C-16), 
124.86 (C-11), 138.13 (C-2), 146.92 (C-13), 147.87 
(C-1), 150.82 (C-14), 159.09 (C-9), 161.63 (C-5), 
166.42 (C-7), 176.27 (C-3) (Fig. S5). Anal. Calcd for 
C16H10O7: C,61.15; H,3.21. Found: C,61.16; H, 
3.24%. ESI-MS: Calcd m/z for C16H10O7: 314.24 
[M].Found: 331.63 [M + H+], 329.20 [M - H+] (Fig. S6). 
 
Compound 3 [Strepsilin]14(Figure 1): m.p.324-
325°C. Rf: 0.4 (hexane:ethyl acetate, 1:1); 1H NMR 
(400 MHz, DMSO-d6): δ2.77 (s, 1H, OH), 3.01 (s, 1H, 
OH), 3.50 (s, 1H, OH), 3.87 (s, 1H, OH), 5.01 (s, 1H, 
OH), 6.19 (d, 1H,J= 1 Hz, Ar-H), 6.19-6.20 (d, 1H,  
J= 4 Hz, Ar-H), 6.77-6.78 (d, 1H,J= 4 Hz, Ar-H), 6.98-
7.01 (m, 2H, Ar-H) (Fig. S7);13C NMR (400 MHz, 
DMSO-d6): δ94.81 (C-8), 99.99 (C-6), 104.66 (C-4), 
116.36 (C-11), 116.67 (C-14), 122.01 (C-15), 122.19 
(C-10), 137.48 (C-2), 145.68 (C-12), 147.21 (C-1), 
148.73 (C-13), 157.97 (C-9), 160.34 (C-5), 164.52  
(C-7), 175.62 (C-3) (Fig. S8). Anal. Calcd for: 
C15H10O5: C,66.67; H,3.73. Found: C,66.62; H,3.74%. 
ESI-MS: Calcd m/z for C15H10O5: 270.23 [M]. Found 
303.66 [M + H+], 301.25 [M - H+] (Fig. S9). 
 
Anti-inflammatory anti-gout activity 
The in vitro anti-inflammatory and anti-gout effects 
of isolated compounds (1-3) were performed using 
cyclooxygenase (COX1/2), 5-lipoxygenase (5-LOX), 
and xanthine oxidase(XO) enzymes, and the results 
were reported in IC50 values (Table I). The 
concentration required for 50% inhibition of COX1 
enzyme for compounds 1,2,3 and AE were found to be 
82.17±2.24, 56.75±0.42, 89.58±0.21 and 42.11±1.13 
µg/mL, respectively, whereas reference drug, 
indomethacin with 5.74±0.68 µg/mL (Table I). From 
 
 
Figure 1 — Chemical representation of isolated dibenzofurans 1-3 from Cladonia corniculata 
 
Table I — Effects of 1-3 and AE on cyclooxygenase (COX1/2), 5-lipoxygenase (5-LOX), and xanthine oxidase (XO) enzymes 
Sample IC50 values (µg/mL)* 
COX1 COX2 5-LOX XO 
1 82.17±2.24 42.18±2.96 71.14±2.17 >100 
2 56.75±0.42 65.18±0.97 49.38±0.28 80.17±0.66 
3 89.58±0.21 85.25±0.54 >100 >100 
AE 42.11±1.13 50.15±1.15 69.18±1.87 82.16±2.18 
Standard 5.74±0.68 6.17±0.71 7.00±0.74 9.10±0.64 
*mean±SD values (n=3) 




the results of COX2 enzyme inhibitory assay, it was 
noticed that the compounds 1,2,3 and AE showed 
potent inhibition efficiency on COX2 enzyme with 
the IC50 of 42.18±2.96, 65.18±0.97, 85.25±0.54 and 
50.15±1.15 µg/mL, respectively, compared to 
indomethacin with 6.17±0.71 µg/mL (Table I). The 
concentration of 1,2 and AE needed to inhibit 5-LOX 
activity at 50% was found to be 71.14±2.17, 
49.38±0.28 and 69.18±1.87 µg/mL, respectively, 
while that of diclofenac was 7.00±0.74 µg/mL 
(Table I). 
 
Inflammation is regulated by higher levels of 
eicosanoids, namely prostaglandins, thromboxanes, 
and leukotrienes in the human body17,18. COXs and  
5-LOX are key enzymes that catalyse the production 
of prostaglandins, thromboxanes and leukotrienes, 
and hydroperoxy fatty acids from arachidonic 
acid19,20. Particularly, inhibition of any one of the 
eicosanoids will activate the other pathway and 
prolongs inflammation21. For instance, inhibition of 
only prostaglandins will lead to elevated levels of 
leukotrienes by activation of the alternative path, i.e., 
5-LOX pathway. Thus, routes of COXs and 5-LOX 
are chosen for the rate-limiting steps to reduce pain, 
as well as inflammation22. Therefore, COXs and  
5-LOX (dual inhibitors) drugs inhibit the production 
of eicosanoids (prostaglandins, thromboxanes, and 
leukotrienes) and entirely prevent inflammation by 
lesser adverse effects21–23. Generally, NSAIDs are the 
drugs of choice to control the production of 
eicosanoids, and eventually relief from 
inflammation24. The outcomes of our study exhibited 
that isolated compounds 1,2 and 3 act as both COXs 
and 5-LOX (dual) inhibitors, whereas compound 3 
prominently inhibit COX1/2 enzymes (Table I). 
 
The isolated compound 2 and AE exhibited 
significant inhibition of XO enzyme with IC50 values 
of 80.17±0.66 and 82.16±2.18 µg/mL, respectively, 
whereas allopurinol with 9.10±0.64 µg/mL (Table I). 
The concentration of compounds 1 and 3 required for 
50% reticence of the XO enzyme was found to be 
above 100 µg/mL (Table I). 
 
XO is an enzyme that catalysed purines 
xanthine/hypoxanthine to form uric acid. To some 
extent, the formation of uric acid does not cause any 
biological effects in human body25. Beyond the limits, 
the higher deposition of uric acid, especially in the 
joints of the human body, leads to painful 
inflammation in joint pains, termed as gout25,26. Also, 
XO is an excellent source for free radicals (containing 
oxygen) that cause inflammatory-related diseases 
such as atherosclerosis and cancer26. Hence, inhibition 
of XO results in controlling gout, as well as its related 
conditions. This study suggests that isolated 
compound 2 possess prominent XO inhibitory effects 
(Table I) that might be supportive in the treatment of 
gout and its complications. Also, based on the 
chemical structures, it is interesting to notice that the 
carboxylic acid (-COOH) group present in compound 
2 plays a crucial role in attaining the biological 
activity. Taken together, C. corniculata scientifically 
proved as a potential source for the management of 
inflammation and gout.  
 
Material and Methods 
 
Collection 
The whole lichen of Cladonia corniculata Ahti & 
Kashiw was collected at Seshachalam Hills, Tirupati, 
Andhra Pradesh, India, in February 2019, and a 
voucher specimen (DB-SVU-2019-3478) has been 
deposited at Department of Botany, Sri Venkateswara 
University, Tirupati, Andhra Pradesh, India. 
 
Extraction and Isolation 
The whole lichen (250 g) was dried and powdered 
and extracted three times with acetone (96%) at 25°C. 
All extracts were combined and concentrated under 
low pressure to obtain an acetone extract of  
C. corniculata (AE,5 g)27. By using column 
chromatography (CC) of mesh size 100-200, AE 
extract (3 g) was fractionated using a hexane/ethyl 
acetate solvent system (step gradient flow), which 
yielded three main fractions, namely F1-3. Similarly, 
F1 (700 mg) subjected to CC using the above 
parameters yielded 1 (450 mg) as sharp yellow 
needles. By using step gradient flow 
dichloromethane/ethyl acetate solvent system, F2 
(250 g) gave 2 (150 mg) as colourless needles. 
Similarly, with dichloromethane/ethyl acetate solvent 
system, and F3 (550 g) yielded 3 (200 mg) as 
colourless needles. All the isolated compounds were 




Cyclooxygenase (COX1/2) inhibitory assay 
The abilities of compounds (1-3) and AE to inhibit 
isoenzymes COX-1/2 were performed using COX 
(ovine/human) inhibitor assay28 kit (Cayman, No.: 
560131). To 10 μL of either COX1 or COX2 added 
960 μL of 0.1 M Tris-HCl buffer and different 
concentrations of test samples and incubated for  




10 min at 37°C. Later 10 μL of 100 μM arachidonic 
acid, after 2 min 1 M HCl of 50 μL and Ellman’s 
reagent, were added. The absorbance was noted 
spectrophotometrically at 410 nm against the blank. 
The percentage of inhibition was calculated with the 
OD values by which IC50 values were determined by 
linear regression.  
 
5-Lipoxygenase (5-LOX) inhibitory assay 
The compounds (1-3) and AE were tested against 
5-LOX (human recombinant) using 5-LOX assay28 kit 
(No. 437996, Sigma Aldrich). To 90 μL of 5- LOX 
enzyme solution added different test sample 
concentrations, 100 μL of de chromogen, and finally 
added 10 μL of the substrate (arachidonic acid) and 
gently shaken for 10 min and absorbance was 
recorded at 490 nm against the blank. The percentage 
of inhibition was calculated with the OD values by 





Xanthine oxidase (XO) inhibitory assay  
All the isolated compounds (1-3) and AE were 
subject to XO inhibitory assay29 using assay Sigma 
Aldrich assay kit. To 10 μL of the substrate (xanthine, 
5 mM), added of sodium phosphate buffer (470 μL), 
different test sample concentrations, and 10 μL of XO 
enzyme and incubated for 5 min at room temperature 
and absorbance was recorded at 295 nm against the 
blank. The percentage of inhibition was calculated 
with the OD values by which IC50 values were 
determined by linear regression. 
 
Conclusion 
To conclude, the results of the present study 
indicated that the dibenzofurans (1-3) from acetone 
extract of C. corniculata displayed anti-inflammatory 
activity by inhibiting COXs and 5-LOX, and anti-gout 
activity by XO inhibition. The key metabolite 
responsible for in vitro activities is claimed to be 
compound 2. The results provide evidence that 
supports the traditional uses of C. corniculata. Also, 
these findings suggest that the lichen C. corniculata 
can take an account as a good natural source of 
remedial medicine for inflammation and gout. Hence, 
the results of the current study remain useful for 
further research to identify the potential bioactive 
molecules from Cladonia genus. The future scope is 
to identify the binding affinity of compounds 1, 2 and 
3 against COXs, 5-LOX, and XO enzymes using 
in silico studies, which eventually helps in selective 
derivatization of parent moieties.  
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